Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alnylam Pharmaceuticals Inc ALNY

Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for... see more

Recent & Breaking News (NDAQ:ALNY)

Alnylam to Webcast Conference Call Discussing Third Quarter 2015 Financial Results

Business Wire November 2, 2015

Alnylam to Report New Clinical Results with Investigational RNAi Therapeutics for the Treatment of Transthyretin-Mediated Amyloidosis at the First European Congress on Hereditary ATTR Amyloidosis

Business Wire October 29, 2015

Alnylam Demonstrates Continued Commitment to Transthyretin-Mediated Amyloidosis Patients with Advancement of ALN-TTRsc02, an Investigational RNAi Therapeutic with Potential for Low Volume, Once Quarterly, Subcutaneous Dose Regimen

Business Wire October 14, 2015

Alnylam Advances New Innovations in RNAi Therapeutics

Business Wire October 13, 2015

Alnylam Initiates Phase 1 Open Label Extension (OLE) Study with ALN-AT3, an Investigational RNAi Therapeutic for the Treatment of Hemophilia and Rare Bleeding Disorders

Business Wire October 8, 2015

Alnylam and Genzyme Announce that Genzyme Opts into ALN-AT3 Hemophilia Program for Development and Commercialization Outside of North America and Western Europe

Business Wire October 1, 2015

Alnylam Granted Summary Judgment by United States District Court for the District of Massachusetts in Tuschl II Patent Inventorship Dispute

Business Wire September 28, 2015

Alnylam and Collaborators Report First-Ever Evidence that Patisiran Reduces Pathogenic, Misfolded Transthyretin (TTR) Monomers and Oligomers in TTR-Mediated Amyloidosis (ATTR Amyloidosis) Patients with Familial Amyloidotic Polyneuropathy (FAP)

Business Wire September 28, 2015

Alnylam Reports Positive Initial Clinical Results for ALN-AS1, an Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1 (ALAS1) for the Treatment of Acute Hepatic Porphyrias

Business Wire September 15, 2015

Alnylam to Webcast Presentations at Upcoming September Conferences

Business Wire September 10, 2015

Alnylam Accelerates Development of ALN-GO1, a Subcutaneously Administered Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)

Business Wire September 8, 2015

ALN-PCSsc Achieves Quarterly and Potentially Bi-Annual Subcutaneous Dose Regimen Profile for Effective LDL-C Lowering in Phase 1 Clinical Study

Business Wire August 30, 2015

Alnylam Pharmaceuticals Reports Second Quarter 2015 Financial Results and Highlights Recent Period Activities

Business Wire August 6, 2015

Alnylam to Webcast Presentation at Canaccord Genuity 35th Annual Growth Conference

Business Wire August 5, 2015

Alnylam to Webcast Conference Call Discussing Second Quarter 2015 Financial Results

Business Wire July 30, 2015

Alnylam Initiates Phase 1/2 Clinical Trial for ALN-AAT, an Investigational RNAi Therapeutic for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease)

Business Wire July 27, 2015

Alnylam Initiates Phase 3 Open Label Extension Study ("APOLLO-OLE") with Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR Amyloidosis)

Business Wire July 20, 2015

Faruqi & Faruqi, LLP is Investigating Alnylam Pharmaceuticals, Inc. (ALNY) on Behalf of its Shareholders

PR Newswire July 17, 2015

Alnylam to Reschedule First RNAi Roundtable Webcast

Business Wire July 16, 2015

Alnylam to Host Second Annual Summer "RNAi Roundtable" Webcast Series

Business Wire July 6, 2015